At Pharma Day 2026, Roche Holding AG outlined plans to integrate artificial intelligence into drug development, including building autonomous, AI-driven laboratories. [4, 9] The company aims for AI tools to contribute to 80% of research portfolio decisions by the end of 2026 as part of its push for “AI independence” in research and development. [9]
Executives said the technology shift forms a key part of Roche’s strategy following a difficult year in 2022 that prompted an end-to-end review of its operations. [4]
Roche expects its marketed portfolio to support growth through the end of the decade, with no upcoming patent cliffs. Executives also highlighted planned launches for giredestrant and fenebrutinib. [4]
By 2026, the company plans to redirect approximately 2 billion Swiss francs in R&D savings toward new programs and productivity initiatives. [9]